Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Valeo Pharma Inc. (C:VPH)

Business Focus: Pharmaceuticals

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for VPH within the last 6 months
See all filings within the past 6 months

Company News

Nov 22, 2019 16:30 ET
CORRECTION FROM SOURCE - Valeo Pharma Announces Change of Auditor
MONTREAL, Nov. 22, 2019 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company,  issued the following news release to amend its news release of October 30, 2019 in connection with its change of auditor from MNP LLP (the "Former Auditor") to PricewaterhouseCoopers LLP (the "Successor Auditor").
Read full article
Nov 14, 2019 05:00 ET
Valeo Pharma Announces Filing of a New Drug Submission for Low Molecular Weight Heparin in Canada
MONTREAL, Nov. 14, 2019 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company,  announced today that the New Drug Submission ("NDS") filed for a low molecular weight heparin ("LMWH") biosimilar has been accepted for review by Health Canada.  
Read full article
See more news stories

Valuation Ratios

Price to Sales - TTM
Price to Book - most recent quarter
Price to Cash Flow per share - TTM
Price to Free Cash Flow per share - TTM
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Nov 30, 201971,18366,182
Nov 15, 20195,0014,566
Oct 31, 20194350
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Valeo Pharma Inc is a Canada-based specialty pharmaceutical company dedicated to the commercialization of prescription products in Canada. With a focus on neurodegenerative diseases, woman's health, and oncology and supportive care, the Company has a portfolio of products and a platform to manage these products through stages of commercialization.

See business summary

Comment On!

Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to (via Easy Blurb).


Search (past week) for $VPH.CA

  • No tweets found